Related references
Note: Only part of the references are listed.Carboxypeptidase D is the Only Enzyme Responsible for Antibody C-Terminal Lysine Cleavage in Chinese Hamster Ovary (CHO) Cells
Zhilan Hu et al.
BIOTECHNOLOGY AND BIOENGINEERING (2016)
It's Time to Regulate: Coping With Product-Induced Nongenetic Clonal Instability in CHO Cell Lines Via Regulated Protein Expression
Shahram Misaghi et al.
BIOTECHNOLOGY PROGRESS (2014)
Chinese hamster ovary K1 host cell enables stable cell line development for antibody molecules which are difficult to express in DUXB11-derived dihydrofolate reductase deficient host cell
Zhilan Hu et al.
BIOTECHNOLOGY PROGRESS (2013)
Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity
Whitney Shatz et al.
MABS (2013)
RNA-Guided Human Genome Engineering via Cas9
Prashant Mali et al.
SCIENCE (2013)
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong et al.
SCIENCE (2013)
Introduction to current and future protein therapeutics: A protein engineering perspective
Paul J. Carter
EXPERIMENTAL CELL RESEARCH (2011)
Highly Efficient Deletion of FUT8 in CHO Cell Lines Using Zinc-Finger Nucleases Yields Cells That Produce Completely Nonfucosylated Antibodies
Laetitia Malphettes et al.
BIOTECHNOLOGY AND BIOENGINEERING (2010)
Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase
Hans Henning von Horsten et al.
GLYCOBIOLOGY (2010)
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells
Matthias Peipp et al.
BLOOD (2008)
Double knockdown of α1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells:: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC
Harue Imai-Nishiya et al.
BMC BIOTECHNOLOGY (2007)
Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: A new strategy for generating completely non-fucosylated recombinant therapeutics
Yutaka Kanda et al.
JOURNAL OF BIOTECHNOLOGY (2007)
Establishment of FUT8 knockout Chinese hamster ovary cells:: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity
N Yamane-Ohnuki et al.
BIOTECHNOLOGY AND BIOENGINEERING (2004)
Production of recombinant protein therapeutics in cultivated mammalian cells
FM Wurm
NATURE BIOTECHNOLOGY (2004)
Fucose: biosynthesis and biological function in mammals
DJ Becker et al.
GLYCOBIOLOGY (2003)
Conditional control of selectin ligand expression and global fucosylation events in mice with a targeted mutation at the FX locus
PL Smith et al.
JOURNAL OF CELL BIOLOGY (2002)
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Expression of GnTIII in a recombinant anti-CD20 CHO production cell line:: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII
J Davies et al.
BIOTECHNOLOGY AND BIOENGINEERING (2001)
Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics
TS Raju et al.
GLYCOBIOLOGY (2000)
Share Paper
